🎉 M&A multiples are live!
Check it out!

Acelyrin Valuation Multiples

Discover revenue and EBITDA valuation multiples for Acelyrin and similar public comparables like Pharming, Julphar, and Vivoryon Therapeutics.

Acelyrin Overview

About Acelyrin

Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.


Founded

2020

HQ

United States of America
Employees

130

Website

acelyrin.com

Financials

LTM Revenue n/a

LTM EBITDA -$301M

EV

-$280M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Acelyrin Financials

Acelyrin has a last 12-month revenue of n/a and a last 12-month EBITDA of -$301M.

In the most recent fiscal year, Acelyrin achieved revenue of n/a and an EBITDA of -$422M.

Acelyrin expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Acelyrin valuation multiples based on analyst estimates

Acelyrin P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$422M -$331M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$41.8M -$250M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Acelyrin Stock Performance

As of March 14, 2025, Acelyrin's stock price is $3.

Acelyrin has current market cap of $276M, and EV of -$280M.

See Acelyrin trading valuation data

Acelyrin Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$280M $276M XXX XXX XXX XXX $-2.43

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Acelyrin Valuation Multiples

As of March 14, 2025, Acelyrin has market cap of $276M and EV of -$280M.

Acelyrin's trades at n/a LTM EV/Revenue multiple, and 0.9x LTM EBITDA.

Analysts estimate Acelyrin's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Acelyrin and 10K+ public comps

Acelyrin Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$280M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.8x XXX XXX XXX
P/E -1.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Acelyrin Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Acelyrin Valuation Multiples

Acelyrin's NTM/LTM revenue growth is n/a

Acelyrin's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $3.2M for the same period.

Over next 12 months, Acelyrin's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Acelyrin's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Acelyrin and other 10K+ public comps

Acelyrin Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -22% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $3.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Acelyrin Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Biopharmaceuticals comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Acelyrin M&A and Investment Activity

Acelyrin acquired  XXX companies to date.

Last acquisition by Acelyrin was  XXXXXXXX, XXXXX XXXXX XXXXXX . Acelyrin acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Acelyrin

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Acelyrin

When was Acelyrin founded? Acelyrin was founded in 2020.
Where is Acelyrin headquartered? Acelyrin is headquartered in United States of America.
How many employees does Acelyrin have? As of today, Acelyrin has 130 employees.
Who is the CEO of Acelyrin? Acelyrin's CEO is Ms. Mina Kim.
Is Acelyrin publicy listed? Yes, Acelyrin is a public company listed on NAS.
What is the stock symbol of Acelyrin? Acelyrin trades under SLRN ticker.
When did Acelyrin go public? Acelyrin went public in 2023.
Who are competitors of Acelyrin? Similar companies to Acelyrin include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Acelyrin? Acelyrin's current market cap is $276M
What is the current EBITDA of Acelyrin? Acelyrin's last 12-month EBITDA is -$301M.
What is the current EV/EBITDA multiple of Acelyrin? Current EBITDA multiple of Acelyrin is 0.9x.
Is Acelyrin profitable? Yes, Acelyrin is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.